Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Po-Ku Chen, Shiow-Jiuan Wey & Der-Yuan Chen. (2022) Interleukin-18: a biomarker with therapeutic potential in adult-onset Still’s disease. Expert Review of Clinical Immunology 18:8, pages 823-833.
Read now
Read now
Masashi Narazaki & Tadamitsu Kishimoto. (2022) Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology 15:5, pages 575-592.
Read now
Read now
Masataka Torigoe, Keisuke Maeshima, Yuhei Kuriyama, Itomi Abe, Takashi Ozaki, Yuichi Omura, Tatsuhito Umeki, Chiharu Imada, Koji Ishii & Hirotaka Shibata. (2021) Effectiveness of subcutaneous tocilizumab in refractory adult Still’s disease: report of three cases and a review of the literature. Modern Rheumatology Case Reports 5:2, pages 365-370.
Read now
Read now
Giulio Cavalli, Nicola Farina, Corrado Campochiaro, Elena Baldissera & Lorenzo Dagna. (2020) Current treatment options and safety considerations when treating adult-onset Still’s disease. Expert Opinion on Drug Safety 19:12, pages 1549-1558.
Read now
Read now
Piero Ruscitti, Alessandro Conforti, Viktoriya Pavlych & Roberto Giacomelli. (2019) Inhibiting inflammatory cytokines in adult onset Still’s disease. Current trends and new therapeutic perspectives. Expert Opinion on Orphan Drugs 7:12, pages 547-554.
Read now
Read now
Dae Hyun Yoo. (2019) Biologics for the treatment of adult-onset still’s disease. Expert Opinion on Biological Therapy 19:11, pages 1173-1190.
Read now
Read now
Santos Castañeda, Dolores Martínez-Quintanilla, José L. Martín-Varillas, Noelia García-Castañeda, Belén Atienza-Mateo & Miguel A. González-Gay. (2019) Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opinion on Biological Therapy 19:4, pages 273-286.
Read now
Read now
Articles from other publishers (39)
Yuko Kaneko, Hideto Kameda, Kei Ikeda, Katsuhisa Yamashita, Ryoto Ozaki & Yoshiya Tanaka. (2023) Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database. International Journal of Rheumatic Diseases.
Crossref
Crossref
Lipeng Qiu, Junze Wang, Mariana Conceição, Shenhuan Liu, Meiyang Yang, Weijun Chen, Miaomiao Long, Xian Cheng, Matthew J.A. Wood & Jinghua Chen. (2023) Tumor-targeted glycogen nanoparticles loaded with hemin and glucose oxidase to promote tumor synergistic therapy. International Journal of Biological Macromolecules 239, pages 124363.
Crossref
Crossref
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, Martin Fleck, Norbert Blank, Johannes-Peter Haas, Ina Kötter, Martin Krusche, Gamal Chehab, Bimba Hoyer, Uta Kiltz, Dorothea Fell, Julia Reiners, Christiane Weseloh, Matthias Schneider & Jürgen Braun. (2022) Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guidelineDiagnostik und Behandlung bei M. Still des Erwachsenen: kurze Zusammenfassung der S2-Leitlinie der Deutschen Gesellschaft für Rheumatologie. Zeitschrift für Rheumatologie 82:S2, pages 81-92.
Crossref
Crossref
Jurgen Sota, Antonio Vitale, Giuseppe Lopalco, Rosa Maria R. Pereira, Heitor F. Giordano, Isabele P.B. Antonelli, Joanna Makowska, Olga Brzezińska, Anna Lewandowska-Polak, Piero Ruscitti, Paola Cipriani, Ilenia Di Cola, Marcello Govoni, Francesca Ruffili, Petros P. Sfikakis, Katerina Laskari, Gaafar Ragab, Mohamed A. Hussein, Stefano Gentileschi, Carla Gaggiano, Francesco La Torre, Armin Maier, Giacomo Emmi, Achille Marino, Francesco Ciccia, Paolo Sfriso, Maria Cristina Maggio, Elena Bartoloni, Claudia Lomater, Mohamed Tharwat Hegazy, Maria Tektonidou, Marília A. Dagostin, Aleksandra Opinc, Gian Domenico Sebastiani, Roberto Giacomelli, Emanuela Del Giudice, Alma Nunzia Olivieri, Abdurrahman Tufan, Riza Kan Kardas, Rossana Nuzzolese, Fabio Cardinale, Ewa Więsik-Szewczyk, Parretti Veronica, Maria Tarsia, Florenzo Iannone, Francesca Della Casa, Claudia Fabiani, Bruno Frediani, Alberto Balistreri, Donato Rigante & Luca Cantarini. (2022) Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry. Seminars in Arthritis and Rheumatism 57, pages 152089.
Crossref
Crossref
Stefan Vordenbäumen, Eugen Feist, Jürgen Rech, Martin Fleck, Norbert Blank, Johannes-Peter Haas, Ina Kötter, Martin Krusche, Gamal Chehab, Bimba Hoyer, Uta Kiltz, Dorothea Fell, Julia Reiners, Christiane Weseloh, Matthias Schneider & Jürgen Braun. (2022) DGRh-S2e-LeitlinieDGRh S2e guidelines. Zeitschrift für Rheumatologie 81:S1, pages 1-20.
Crossref
Crossref
Chihiro Imaizumi, Masaya Saito, Fumito Abe, Hajime Kaga, Ayano Saito, Mizuho Nara, Saeko Kameyama, Hiroshi Miura, Hitoshi Ogasawara, Takeo Hirakawa, Makito Mizunuma, Makiko Satoh, Atsushi Komatsuda, Yukihiro Terada & Naoto Takahashi. (2022) Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab. Internal Medicine 61:20, pages 3137-3140.
Crossref
Crossref
Shijia Rao, Lemuel Shui-Lun Tsang, Ming Zhao, Wei Shi & Qianjin Lu. (2022) Adult-onset Still’s disease: A disease at the crossroad of innate immunity and autoimmunity. Frontiers in Medicine 9.
Crossref
Crossref
Takaharu Ikeda, Kae Yokoyama & Tamihiro Kawakami. (2022) Heliotrope‐like manifestation of adult‐onset Still disease with macrophage activation syndrome: A case‐based review. The Journal of Dermatology 49:7, pages 736-740.
Crossref
Crossref
Bowen Xu, Jian Wang, Xiaoying Meng & Binghao Bao. (2022) Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976–2020). Frontiers in Public Health 10.
Crossref
Crossref
Dai Kishida, Takanori Ichikawa, Ryota Takamatsu, Shun Nomura, Masayuki Matsuda, Wataru Ishii, Tatsuo Nagai, Sadahiro Suzuki, Ken-ichi Ueno, Naoki Tachibana, Yasuhiro Shimojima & Yoshiki Sekijima. (2022) Clinical characteristics and treatment of elderly onset adult-onset Still’s disease. Scientific Reports 12:1.
Crossref
Crossref
Kuo-Tung Tang, Chia-Wei Hsieh, Hsin-Hua Chen, Yi-Ming Chen, Shih-Hsin Chang, Po-Hao Huang, Joung-Liang Lan & Der-Yuan Chen. (2021) The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clinical Rheumatology 41:2, pages 557-566.
Crossref
Crossref
Yugo Horiuchi, Kenichi Hashimoto, Hideyuki Horikoshi, Azusa Sano, Yusuke Kawamura, Naoya Fujita, Motohiro Kimata, Yosuke Ono, Yasuhiro Obuchi, Arisa Makino, Mayuko Kaneko, Fumihiko Kimura, Kenji Itoh & Yuji Tanaka. (2022) Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: A case report. Medicine 101:28, pages e29354.
Crossref
Crossref
Sébastien Ottaviani & Bastien Léger. 2022. L'actualité Rhumatologique 2022. L'actualité Rhumatologique 2022
215
224
.
Diogo Esperança Almeida, Emanuel Costa, Joana Sousa Neves, Marcos Cerqueira & Ana Roxo Ribeiro. (2021) The Role of Tocilizumab in the Treatment of Adult-Onset Still Disease—Report of a Tertiary Single-Center Experience. JCR: Journal of Clinical Rheumatology 27:8S, pages S875-S876.
Crossref
Crossref
Joana Rodrigues, Daniela Santos-Faria, Joana Silva, Soraia Azevedo, Francisca Guimarães, Diogo Esperança Almeida, Filipa Teixeira, Daniela Peixoto, Sérgio Alcino, Carmo Afonso & José Tavares-Costa. (2021) Treating Adult-Onset Still Disease With Tocilizumab. JCR: Journal of Clinical Rheumatology 27:8S, pages S414-S415.
Crossref
Crossref
Piero Ruscitti, Onorina Berardicurti, Roberto Giacomelli & Paola Cipriani. (2021) The clinical heterogeneity of adult onset Still’s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. Seminars in Immunology 58, pages 101632.
Crossref
Crossref
Po-Ku Chen, Kai-Jieh Yeo, Po-Hao Huang, Shih-Hsin Chang, Ching-Kun Chang, Joung-Liang Lan & Der-Yuan Chen. (2021) Increased Lipid Peroxidation May Be Linked to Ferritin Levels Elevation in Adult-Onset Still’s Disease. Biomedicines 9:11, pages 1508.
Crossref
Crossref
Po-Ku Chen, Joung-Liang Lan, Po-Hao Huang, Jye-Lin Hsu, Ching-Kun Chang, Ni Tien, Hui-Ju Lin & Der-Yuan Chen. (2021) Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still’s Disease From COVID-19. Frontiers in Immunology 12.
Crossref
Crossref
Po-Ku Chen & Der-Yuan Chen. (2021) An Update on the Pathogenic Role of Macrophages in Adult-Onset Still’s Disease and Its Implication in Clinical Manifestations and Novel Therapeutics. Journal of Immunology Research 2021, pages 1-11.
Crossref
Crossref
Ana M. Giménez-Arnau, Laurence de Montjoye, Riccardo Asero, Massimo Cugno, Kanokvalai Kulthanan, Yuhki Yanase, Michihiro Hide & Allen P. Kaplan. (2021) The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. The Journal of Allergy and Clinical Immunology: In Practice 9:6, pages 2195-2208.
Crossref
Crossref
Seher Kır, Metin Özgen & Sezgin Zontul. (2020) Adult‐onset still’s disease and treatment results with tocilizumab. International Journal of Clinical Practice 75:3.
Crossref
Crossref
Stylianos Tomaras, Carl Christoph Goetzke, Tilmann Kallinich & Eugen Feist. (2021) Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach. Journal of Clinical Medicine 10:4, pages 733.
Crossref
Crossref
Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, Giacomo De Luca, Elena Baldissera, Giulio Cavalli & Lorenzo Dagna. (2021) Drug retention rates of biological agents in adult onset Still's disease. Seminars in Arthritis and Rheumatism 51:1, pages 1-6.
Crossref
Crossref
Seong Yeon Park & Kwang-Hoon Lee. (2021) Adult-onset Still’s Disease after BNT162b2 mRNA COVID-19 Vaccine. Journal of Korean Medical Science 36:50.
Crossref
Crossref
N. Blank & S. O. Schönland. (2020) Autoinflammatorische Syndrome und Amyloid-A-AmyloidoseAutoinflammatory syndromes and AA amyloidosis. Zeitschrift für Rheumatologie 79:7, pages 649-659.
Crossref
Crossref
Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Joerg Christoph Henes, Joern Kekow, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Eva Seipelt, Christof Specker & Eugen Feist. (2020) Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the Rheumatic Diseases 79:8, pages 1090-1097.
Crossref
Crossref
Mirna Reihl Crnogaj, Darija Čubelić, Antonija Babić, Miroslav Mayer & Branimir Anić. (2020) Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review. Rheumatology International 40:8, pages 1317-1325.
Crossref
Crossref
Aleksander Lenert, GYeon Oh, Michael J Ombrello & Sujin Kim. (2020) Clinical characteristics and comorbidities in adult-onset Still’s disease using a large US administrative claims database. Rheumatology 59:7, pages 1725-1733.
Crossref
Crossref
Serena Colafrancesco, Cristiano Alessandri, Fabrizio Conti & Roberta Priori. (2020) COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?. Autoimmunity Reviews 19:7, pages 102573.
Crossref
Crossref
Sheng Li, Siting Zheng, Shunli Tang, Yunlei Pan, Shan Zhang, Hong Fang & Jianjun Qiao. (2019) Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease. Clinical Reviews in Allergy & Immunology 58:1, pages 71-81.
Crossref
Crossref
Stéphane Mitrovic, Eugen Feist & Bruno Fautrel. 2020. Periodic and Non-Periodic Fevers. Periodic and Non-Periodic Fevers
93
132
.
Meng-Yan Wang, Jin-Chao Jia, Cheng-De Yang & Qiong-Yi Hu. (2019) Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review. Chinese Medical Journal 132:23, pages 2856-2864.
Crossref
Crossref
Bartlomiej Wawrzycki, Dorota Krasowska, Aldona Pietrzak, Ewa Wielosz, Maria Majdan & Torello Lotti. (2019) Urticarial rash, fever, and arthritis: A case of refractory Adult‐onset Still's disease with good response to tocilizumab. Dermatologic Therapy 32:5.
Crossref
Crossref
Jumpei Saito, Naho Yakuwa, Kayoko Kaneko, Chinatsu Takai, Mikako Goto, Ken Nakajima, Akimasa Yamatani & Atsuko Murashima. (2019) Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology 58:8, pages 1505-1507.
Crossref
Crossref
E. L. Nasonov. (2019) Therapy with canakinumab for adult-onset still's disease. Rheumatology Science and Practice 56, pages 35-40.
Crossref
Crossref
Charlotte Girard-Guyonvarc’h & Cem Gabay. (2019) Les biothérapies dans la prise en charge de la maladie de Still de l’adulte. Revue du Rhumatisme 86:2, pages 119-121.
Crossref
Crossref
Masashi Narazaki & Tadamitsu Kishimoto. (2018) The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences 19:11, pages 3528.
Crossref
Crossref
Eugen Feist, Stéphane Mitrovic & Bruno Fautrel. (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nature Reviews Rheumatology 14:10, pages 603-618.
Crossref
Crossref
Paolo Sfriso, Sara Bindoli & Paola Galozzi. (2018) Adult-Onset Still’s Disease: Molecular Pathophysiology and Therapeutic Advances. Drugs 78:12, pages 1187-1195.
Crossref
Crossref